Pharmacokinetics of Daunorubicin in Treating Young Patients With Cancer

• Status: Active, not recruiting
• Trial end date: 0000-00-00
• Target enrollment: 107
• Participant gender: Both

Summary

RATIONALE: Collecting and storing samples of blood from patients with cancer to study in the laboratory may help doctors learn more about how patients respond to treatment with certain chemotherapy drugs.

PURPOSE: This laboratory study is looking at the pharmacokinetics of daunorubicin in treating young patients with cancer.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Children's Oncology Group
• Collaborator: National Cancer Institute (NCI)
• Treatments: Daunorubicin
• Last Updated: 2016-09-06

Criteria

DISEASE CHARACTERISTICS:

• Diagnosis of any malignancy

• Must be receiving a chemotherapy regimen that includes daunorubicin hydrochloride administered as an infusion of any duration for < 24 hours on either a 1- or a 2-day schedule, including bolus and all short infusion schedules

PATIENT CHARACTERISTICS:

• Not pregnant or nursing

• No significant uncontrolled systemic illness

• Large implanted prostheses allowed (should not undergo dual energy x-ray absorptiometry scan)

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics